Quotient Bioresearch forms Quotient Clinical
Quotient Bioresearch, a provider of drug development services based in Cambridgeshire, UK, has acquired Charles River Laboratories" Edinburgh clinical research facility.
Quotient Bioresearch, a provider of drug development services based in Cambridgeshire, UK, has acquired Charles River Laboratories" Edinburgh clinical research facility.
The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new division within Quotient to be called Quotient Clinical.
Quotient Clinical will have a workforce of approximately 160 medical, scientific and clinical staff across the two facilities in Edinburgh and Nottingham. Its main role will be to provide early development services from First-in-Human (FIH) to Phase 2a patient studies to pharmaceutical and biotechnology customers.
Paul Cowan, chairman and ceo of Quotient, said: "The creation of Quotient Clinical represents the next step in expanding the specialised services we offer pharmaceutical and biotech customers worldwide."
Mark Egerton, formerly ceo of Pharmaceutical Profiles, will head Quotient Clinical.